Aromatase inhibitors in men: effects and therapeutic options
Open accessThe DOI matches its Crossref record; 93 of the 103 references it cites were found in a registry or an index; 7 of the 157 sources its claims cite were checked for support.
Abstract
Aromatase inhibitors effectively delay epiphysial maturation in boys and improve testosterone levels in adult men Therefore, aromatase inhibitors may be used to increase adult height in boys with gonadotropin-independent precocious puberty, idiopathic short stature and constitutional delay of puberty. Long-term efficacy and safety of the use of aromatase inhibitors has not yet been established in males, however, and their routine use is therefore not yet recommended.
Overview
CoChat Summary
TL;DR
Aromatase inhibitors lower estradiol in males and can raise gonadotropins/testosterone, delay epiphysial maturation in boys, and sometimes increase predicted adult height. The review concludes they are promising in selected settings but not yet recommended routinely because long-term efficacy and safety remain uncertain.
Key findings
- In boys with idiopathic short stature treated with letrozole 2.5 mg once daily for 2 years, bone age progressed significantly more slowly and predicted adult height increased by 5.9 cm, while growth velocity was similar to placebo.
- In boys with constitutional delay of puberty, testosterone plus letrozole increased growth velocity and slowed epiphysial maturation, leading to a significant increase in predicted adult height.
- In older men, anastrozole 1 mg daily for 12 weeks doubled mean bioavailable testosterone; atamestane 100 mg once daily for 36 weeks increased total testosterone by 40%, but these studies did not show beneficial effects on muscle strength, body composition, or quality of life.
- For gynecomastia, anastrozole 6 months did not significantly improve outcomes versus placebo in pubertal boys, and tamoxifen was reported to be much more effective than anastrozole for preventing gynecomastia in men receiving bicalutamide.
Methods
- Narrative review of published evidence on aromatase inhibitors in males, covering boys and adult men, with discussion of case reports, uncontrolled studies, and controlled trials.
- The paper summarizes specific clinical studies in settings including idiopathic short stature, constitutional delay of puberty, late-onset hypogonadism, obesity, gynecomastia, and male fertility.
- Main analysis is qualitative synthesis of reported endocrine, skeletal, and clinical outcomes across studies, rather than a new original dataset.
Limitations
- The paper states that long-term efficacy and safety have not yet been established in males, so routine use is not recommended.
- The text makes evident that much of the evidence base is small, heterogeneous, and often uncontrolled (e.g., “three small studies,” case studies, and studies with relatively small numbers), which limits certainty.
- The paper states that for older men, the testosterone-raising effect may be too weak, especially in those with the lowest baseline testosterone levels who might benefit most.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 5 Not valid · 76 Not checked · 31 Own results and interpretations
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“All adult aromatase-deficient men demonstrated a remarkably low bone mass and unfused epiphyses leading to linear growth into adulthood and above-average body length.”
§ Aromatase inhibitors in men: effects and therapeutic options > Background > Phenotype of aromatase deficiency and excess
What the sources say
- Not checked — no full text of the sourcecites [17] source
- Could not verifycites [18] sourceExperimental — accuracy not yet measured
Our copy of 10.1016/j.bone.2008.05.011 holds only the institutional repository (IRIS UNIMORE) metadata record — the title, author list and 'Contributo su RIVISTA / Articolo su rivista' navigation text, with no section labels or page numbers and no article body. Five searches (unfused epiphyses / linear growth / tall stature; bone mineral density and Z-score; epiphyseal plate fusion and auxology; estrogen replacement treatment effects; CYP19A1 mutation with stature and osteoporosis) each returned only that same metadata passage, so nothing in our copy speaks to epiphyseal fusion, continued growth into adulthood, body length, or bone mass in aromatase-deficient men. Note also that the claim generalizes to 'all adult aromatase-deficient men', which could not be settled by this single-case report even had its full text been available. (LLM, conf=0.72)
- Not checked — no full text of the sourcecites [19] source
- Could not verifycites [20] sourceExperimental — accuracy not yet measured
Our copy of Stratakis et al. (1998) concerns the aromatase EXCESS syndrome, not aromatase deficiency: the Abstract and Subjects sections describe a three-generation kindred with autosomal dominant P450arom overexpression (a 9-yr-old propositus with gynecomastia and advanced bone age of 13.5 yr, his 7.5-yr-old sister with isosexual precocity, father, paternal grandmother), treated with testolactone plus a GnRH analog to DELAY skeletal maturation. No passage addresses aromatase-deficient men, unfused epiphyses, continued linear growth into adulthood, tall stature, or low bone mass (searched: 'aromatase deficiency epiphyses unfused linear growth tall stature', 'bone mineral density bone age advanced skeletal maturation', 'aromatase deficiency estrogen excess Morishima Fisher', 'introduction epiphyseal fusion knockout'). Since our copy does not speak to the claim's point at all — and contains no contrary statement about aromatase deficiency — the attribution can be neither confirmed nor disputed. (LLM, conf=0.72)
- Could not verifycites [21] sourceExperimental — accuracy not yet measured
Our copy of Shozu et al. (2003) concerns the opposite condition — aromatase gain-of-function with estrogen excess — and never describes aromatase-deficient men; the Abstract states that 'Excess estrogen in boys causes gynecomastia, a premature growth spurt, early fusion of epiphyses, and decreased adult height,' and the patients (patient 1, patient 3) stopped growing early with heights below the 1st percentile. The discussion also notes that 'men with this condition are not thought to be at risk for osteoporosis,' so nothing here supports the claimed remarkably low bone mass, unfused epiphyses, continued linear growth into adulthood, or above-average height. Searches for aromatase deficiency, unfused epiphyses, eunuchoid/tall stature and bone mineral density returned only estrogen-excess material, so the claim's point is not addressed by this source (it is not, however, credited in our copy to any other named work). (LLM, conf=0.72)
- Not checked — no full text of the sourcecites [22] source
- Not checked — no full text of the sourcecites [23] source
boostedstates a causen = 7- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Uncontrolled studies using anastrozole, testolactone or letrozole have shown some evidence for a positive effect on sperm concentration and motility [49-51].”
§ Aromatase inhibitors in men: effects and therapeutic options > Background > Effects of aromatase inhibition on release of follicle-stimulating hormone and spermatogenesis
What the sources say
- Not checked — no full text of the sourcecites [49] source
- Could not verifycites [50] sourceExperimental — accuracy not yet measured
The Abstract and Discussion describe anastrozole, testolactone, and letrozole in the treatment of testotoxicosis, with outcomes such as growth and predicted adult height. Searches for sperm concentration, motility, and semen outcomes found no passage reporting that these treatments improved either sperm measure. (LLM, conf=0.74)
- Not checked — no full text of the sourcecites [51] source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Estrogen excess in turn has been associated with premature closure of the epiphyses, gynecomastia and low gonadotropin and testosterone levels.”
§ Aromatase inhibitors in men: effects and therapeutic options > Background
What the sources say
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Men with estrogen deficiency caused by a mutation in the CYP19 gene suffer from low bone mineral density (BMD) and unfused epiphyses, and have high gonadotropin and testosterone levels [1].”
§ Aromatase inhibitors in men: effects and therapeutic options > Background
What the sources say
- Not checked — no full text of the sourcecites [1] source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Estrogen excess in turn has been associated with premature closure of the epiphyses, gynecomastia and low gonadotropin and testosterone levels.”
§ Aromatase inhibitors in men: effects and therapeutic options > Background
What the sources say
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
84 more claims
Create a free account to see all 112 claims and to verify the 18 references still open.
- Probably not a substantial claim. 4
- It may state two separate claims as one. 18
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Vandekerckhove P Lilford R Vail A Hughes E Clomiphene or tamoxifen for idiopathic oligo/asthenospermia Cochrane Database Syst Rev 2000 2 CD000151 10796497”
Cited work 10.1002/14651858.cd000151 · retracted 1996-10-21 · notice 10.1002/14651858.cd000151 · this paper published 2011
Citations
Cites
1 retracted
Clomiphene or tamoxifen for idiopathic oligo/asthenospermia
Vandekerckhove, P., Lilford, R., Vail, A., Hughes, E., & Hafez, M. (1996) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000151 · Cited by 109
RetractedA Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052258 · Cited by 1,577
Morishima, A., Grumbach, M. M., Simpson, E. R., Fisher, C., & Qin, K. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.12.8530621 · Cited by 1,416
Effect of testosterone and estradiol in a man with aromatase deficiency
Carani, C., Qin, K., Simoni, M., Faustini-Fustini, M., Serpente, S., Boyd, J., Korach, K. S., & Simpson, E. R. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707103370204 · Cited by 1,151 · cited 1×
“To date, eight males with aromatase deficiency have been described: seven adults [17-23] and one newborn [24].”
Södergard, R., Bäckström, T., Shanbhag, V., & Carstensen, H. (1982) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(82)90038-3 · Cited by 1,080
The Decline of Androgen Levels in Elderly Men and Its Clinical and Therapeutic Implications
Kaufman, J. M., & Vermeulen, A. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0013 · Cited by 1,079
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
Investigation, treatment and monitoring of late-onset hypogonadism in males
Wang, C., Nieschlag, E., Swerdloff, R., Behre, H. M., Hellstrom, W. J., Gooren, L. J., Kaufman, J. M., Legros, J.-J., Lunenfeld, B., Morales, A., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0601 · Cited by 867
Falahati-Nini, A., Riggs, B. L., Atkinson, E. J., O’Fallon, W. M., Eastell, R., & Khosla, S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10942 · Cited by 757 · cited 2×
“In experimental settings, selective withdrawal of estradiol in men was associated with an increase in markers of bone resorption [30,81].”
Geisler, J., Haynes, B., Anker, G., Dowsett, M., & Lønning, P. E. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.751 · Cited by 604
Cited by
Cooke, P. S., Nanjappa, M. K., Ko, C., Prins, G. S., & Hess, R. A. (2017) · Physiological Reviews · doi:10.1152/physrev.00018.2016 · Cited by 466
Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0037 · Cited by 304
Dean, J. D., McMahon, C. G., Guay, A. T., Morgentaler, A., Althof, S. E., Becher, E. F., Bivalacqua, T. J., Burnett, A. L., Buvat, J., El Meliegy, A., et al. (2015) · The Journal of Sexual Medicine · doi:10.1111/jsm.12952 · Cited by 159
Obesity, estrogens and adipose tissue dysfunction - implications for pulmonary arterial hypertension
Mair, K. M., Gaw, R., & MacLean, M. R. (2020) · Pulmonary Circulation · doi:10.1177/2045894020952023 · Cited by 129
Helo, S., Ellen, J., Mechlin, C., Feustel, P., Grossman, M., Ditkoff, E., & McCullough, A. (2015) · The Journal of Sexual Medicine · doi:10.1111/jsm.12944 · Cited by 102
Metadata
- Authors
- de Ronde, W., & de Jong, F. H.
- Venue
- Reproductive Biology and Endocrinology
- Published
- 2011
- Volume
- 9
- Issue
- 1
- Pages
- 93
- ISSN
- 1477-7827 (ISSN-L)
- PMC
- PMC3143915
- OpenAlex
- W2104663096
- Cited by
- 155
- References
- 103
- Citations by year
- 2026: 6 · 2025: 14 · 2024: 10 · 2023: 18 · 2022: 7 · 2021: 11 · 2020: 11 · 2019: 12 · 2018: 6 · 2017: 21 · 2016: 9 · 2015: 16 · 2014: 8 · 2013: 3 · 2012: 3
- FWCI
- 0.69
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Reproductive Biology and Endocrinology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Keywords
- aromatase inhibitors, male patients, precocious puberty, idiopathic short stature, constitutional delay of growth and puberty, adult height, testosterone levels, long-term efficacy and safety
- MeSH terms
- Adolescent, Body Height, Bone Development, Breast, Child, Growth Disorders, Humans, Male, Obesity, Puberty, Puberty, Precocious, Spermatogenesis, Testosterone, Aromatase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aromatase inhibitors in men: effects and therapeutic options. https://app.cochat.ai/papers/10.1186/1477-7827-9-93
- The paper
- de Ronde, W., & de Jong, F. H. (2011). Aromatase inhibitors in men: effects and therapeutic options. Reproductive Biology and Endocrinology. https://doi.org/10.1186/1477-7827-9-93
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.